Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Unresectable intrahepatic cholangiocarcinoma (ICC) signifies a poor prognosis with limited treatment options beyond systemic chemotherapy. This study's purpose was to evaluate the safety, efficacy, and potential for downstaging to resection of yttrium-90 (Y90) radioembolization for treatment of unresectable ICC.
Materials And Methods: From 2004 to 2020, 136 patients with unresectable ICC were treated with radioembolization at a single institution. Retrospective review was performed of a prospectively collected database. Outcomes were (1) biochemical and clinical toxicities, (2) local tumor response, (3) time to progression, and (4) overall survival (OS) after Y90. Univariate/multivariate survival analyses were performed. A subgroup analysis was performed to calculate post-resection recurrence and OS in patients downstaged to resection after Y90.
Results: Grade 3+ clinical and biochemical toxicities were 7.6% (n = 10) and 4.9% (n = 6), respectively. Best index lesion response was complete response in 2 (1.5%), partial response in 42 (32.1%), stable disease in 82 (62.6%), and progressive disease in 5 (3.8%) patients. Median OS was 14.2 months. Solitary tumor (P < 0.001), absence of vascular involvement (P = 0.009), and higher serum albumin (P < 0.001) were independently associated with improved OS. Eleven patients (8.1%) were downstaged to resection and 2 patients (1.5%) were bridged to transplant. R0-resection was achieved in 8/11 (72.7%). Post-resection median recurrence and OS were 26.3 months and 39.9 months, respectively.
Conclusion: Y90 has an acceptable safety profile and high local disease control rates for the treatment of unresectable ICC. Downstaging to resection with > 3 years survival supports the therapeutic role of Y90 for unresectable ICC.
Level Of Evidence: Level 3, single-arm single-center cohort study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00270-022-03183-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Liver Transplant for Intrahepatic Cholangiocarcinoma: Current Evidence and Clinical Practice Recommendations.
J Gastrointest Surg
September 2025
Department of Surgery, Massachusetts General Hospital, Boston, MA. Electronic address:
Intrahepatic cholangiocarcinoma (iCCA) incidence is increasing globally and is associated with poor prognosis. Surgical resection remains the main curative treatment. However, many patients present with unresectable disease or underlying liver dysfunction, precluding resection.
View Article and Find Full Text PDFIs it a new era for intrahepatic cholangiocarcinoma?
Crit Rev Oncol Hematol
September 2025
Medical Oncology Unit, Department of Molecular and Clinical Sciences, AOU delle Marche, Polytechnic University of Marche, Ancona, Italy. Electronic address:
Intrahepatic cholangiocarcinoma (iCCA) is increasingly considered as a separate entity from other biliary tract cancers (BTCs), due to differences in aetiology, risk factors, pathobiology, anatomical and molecular biology characteristics. Surgery is the only curative option for the ∼ 30 % who are diagnosed with a resectable disease, while liver-directed therapies (LDTs - i.e.
View Article and Find Full Text PDFScreening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.
J Hepatocell Carcinoma
August 2025
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Background: Conversion therapies after immune checkpoint inhibitors (ICIs) plus tyrosine-kinase inhibitors (TKIs) provide curative surgery chance and prolong survival for unresectable hepatocellular carcinoma (uHCC). However, only some patients have the opportunity to receive conversion therapies. To this end, we aimed to develop and validate a machine-learning model to identify patients who may have the chance to undergo conversion therapy.
View Article and Find Full Text PDFOutcomes of stereotactic body radiotherapy for unresectable cholangiocarcinoma: a meta-analysis and systematic review.
PeerJ
September 2025
Department of Radiotherapy, Yantai Yuhuangding Hospital, Yantai, China.
Background: Stereotactic body radiotherapy (SBRT) is an effective treatment for various malignancies. This meta-analysis aimed to determine the prognostic outcomes and toxicities of SBRT for unresectable cholangiocarcinoma (CC) using the most recent evidence.
Methods: The review protocol was registered on PROSPERO (CRD42023393642).
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.
Lancet Oncol
August 2025
Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China. Electro
Background: The optimal conversion regimen that allows more patients with unresectable biliary tract cancer to access surgery remains unclear; there is currently no standard conversion therapy for biliary tract cancer in China, with commonly used regimens including immunotherapy-based combinations and local therapy. The ZSAB-TransGOLP study aimed to assess the efficacy and safety of tislelizumab plus lenvatinib and GEMOX (gemcitabine plus oxaliplatin) chemotherapy (GOLP) in patients with this disease.
Methods: This single-arm, phase 2 study was conducted at two centres in China.